

19
Paper Number

REQUEST FOR ACCESS

DATE: 4/26/94
SERIAL NUMBER: ~~621988~~ 599,543
FILING DATE: 10/18/90
APPLICANTS: Oppermann

SIR:

RECEIVED
94 APR 26 AM 3:00
GROUP 180

THE UNDERSIGNED HEREBY RESPECTFULLY REQUESTS ACCESS TO THE FILE HISTORY OF THE FOLLOWING ABANDONED APPLICATION WHICH WAS REFERRED TO IN U.S. PATENT NUMBER 5266623 OR PRINTED APPLICATION _____.

RESPECTFULLY SUBMITTED,

Victor Messinger

OFFICIAL USE ONLY

Initials
File Information Unit

approved
[Signature]
4-26-94

United States Patent [19]

Oppermann et al.



US005266683A

[11] Patent Number: **5,266,683**

[45] Date of Patent: *** Nov. 30, 1993**

[54] OSTEOGENIC PROTEINS

[75] Inventors: Hermann Oppermann, Medway;
Engin Ozkaynak, Milford; Thangavel
Kuberasampath, Medway; David C.
Rueger, Hopkinton; Roy H. L. Pang,
Medway, all of Mass.

[73] Assignee: Stryker Corporation, Kalamazoo,
Mich.

[*] Notice: The portion of the term of this patent
subsequent to Nov. 2, 2010 has been
disclaimed.

[21] Appl. No.: 841,646

[22] Filed: Feb. 21, 1992

Related U.S. Application Data

- [60] Continuation-in-part of Ser. No. 827,052, Jan. 28, 1992, Pat. No. 5,250,302, Ser. No. 579,865, Oct. 7, 1990, Pat. No. 5,108,753, Ser. No. 621,849, Dec. 4, 1990, abandoned, Ser. No. 621,988, Dec. 4, 1990, abandoned, Ser. No. 810,560, Dec. 20, 1991, abandoned, Ser. No. 569,920, Aug. 20, 1990, abandoned, Ser. No. 600,024, Oct. 18, 1990, abandoned, Ser. No. 599,543, Oct. 18, 1990, abandoned, Ser. No. 616,374, Nov. 21, 1990, Pat. No. 5,162,114, and Ser. No. 483,913, Feb. 21, 1990, Pat. No. 5,171,574, said Ser. No. 827,052, is a division of Ser. No. 179,406, Apr. 8, 1988, Pat. No. 4,568,590, said Ser. No. 579,865, is a division of Ser. No. 179,406, Apr. 8, 1988, said Ser. No. 621,849, is a division of Ser. No. 232,630, Aug. 15, 1988, abandoned, which is a continuation-in-part of Ser. No. 179,406, Aug. 15, 1988, said Ser. No. 621,988, is a division of Ser. No. 315,342, Feb. 22, 1989, Pat. No. 5,011,691, which is a continuation-in-part of Ser. No. 232,630, Feb. 23, 1989, said Ser. No. 810,560, is a continuation of Ser. No. 660,162, Feb. 22, 1991, abandoned, which is a continuation of Ser. No. 422,699, Oct. 17, 1989, abandoned, which is a continuation-in-part of Ser. No. 315,342, Oct. 17, 1989, said Ser. No. 569,920, is a continuation-in-part of Ser. No. 422,699, Oct. 17, 1989, and Ser. No. 483,913, Oct. 17, 1989, which is a continuation-in-part of Ser. No. 422,613, Oct. 17, 1989, Pat. No. 4,975,526, which is a continuation-in-part of Ser. No. 315,342, Oct. 17, 1989, said Ser. No. 600,024, is a continuation-in-part of Ser. No. 569,920, Oct. 17, 1989, said Ser. No. 599,543, is a continuation-in-part of Ser. No. 569,920, Oct. 17, 1989.

- [51] Int. Cl.³ A61K 37/02; C07K 5/00;
C07K 7/00; C07K 15/00
[52] U.S. Cl. 530/326; 530/327;
530/328; 530/350; 530/395; 530/840
[58] Field of Search 530/326, 327, 328, 395,
530/840, 300, 350

[56] References Cited

U.S. PATENT DOCUMENTS

- 4,172,128 10/1979 Thiele et al. 424/95
4,294,753 10/1981 Urist 530/356
4,394,370 7/1983 Jefferies 424/15
4,434,094 2/1984 Seyedin et al. 530/356
4,455,256 6/1984 Urist 530/356
4,563,350 1/1986 Nathan et al. 424/95
4,563,489 1/1986 Urist 524/21

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

- 069260 6/1982 European Pat. Off. .
(List continued on next page.)

OTHER PUBLICATIONS

- Canalis et al., Science 210:1021-1023 (1980).
Glowacki et al., Lancet 3:959-963 (1981).
Pecoli, Collagen Rel. Res. 1:209-226 (1981).
Sampath et al., Proc. Natl. Acad. Sci. USA
78:7599-7603 (1981).

(List continued on next page.)

Primary Examiner—Nathan M. Nutter
Attorney, Agent, or Firm—Testa, Hurwitz & Thibault

[57] ABSTRACT

Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.

58 Claims, 47 Drawing Sheets